Harmony Biosciences Holdings, Inc (NASDAQ:HRMY) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Luis Sanay – Head of Investor RelationsJeffrey Dayno – President & Chief Executive OfficerJeffrey Dierks – Chief Commercial OfficerKumar Budur – Chief Medical OfficerSandip Kapadia – Chief Financial Officer & Chief Administrative Officer Conference Call Participants Charles…
Hailshadow Solid Biosciences Inc. (NASDAQ:SLDB) is a pre-revenue company focused on gene therapy innovation for neuromuscular and cardiac conditions. Its flagship one-dose drug therapy, SGT-003 for Duchenne muscular dystrophy [DMD], is expected to be tested in its first patient in Q2 2024, with initial data in mid-2024 and functional data in Q4 2024. If the…
Pulse Biosciences Inc (NASDAQ:PLSE) Q4 2023 Results Conference Call March 28, 2024 4:30 PM ET Company Participants Philip Taylor – IRKevin Danahy – President & CEODarrin Uecker – CTO & DirectorMitch Levinson – Chief Strategy OfficerMike Koffler – Vice President of FinanceBob Duggan – Executive Chairman Conference Call Participants Brad Bowers – Mizuho Securities Operator…
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Conference Call March 26, 2024 5:00 PM ET Company Participants Susan Pietropaolo – Managing Director-Corporate Communications & Investor RelationsWilliam Rice – Chairman, President & Chief Executive OfficerFletcher Payne – Senior Vice President and Chief Financial OfficerRafael Bejar – Senior Vice President & Chief Medical Officer Conference Call Participants…
Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Conference Call February 21, 2024 5:00 PM ET Company Participants Pia Eaves – Vice President of Investor Relations Terry Rosen – CEO Jennifer Jarrett – COO Dimitry Nuyten – CMO Bob Goeltz – CFO Juan Jaen – President Conference Call Participants Terence Flynn – Morgan Stanley Peter Lawson…
Pressure BioSciences, Inc. (OTC:PBIO) Acquisition of Uncle Bud’s Conference Call February 5, 2024 4:30 PM ET Company Participants Richard Schumacher – Founder, President and CEO Jeff Peterson – Chairman of the Board John Hollister – Head of Sales and Marketing Bruno Schiavi – President of Uncle Bud’s Garrett Greller – Director of Marketing and Co-Founder…
Alexander Farnsworth/iStock via Getty Images In November 2023, I wrote about Caribou Biosciences (NASDAQ:CRBU), rating it a buy based on the data with its off the shelf CAR-T therapeutic CB-010, from which I expected more positive data in 2024, its pipeline and plentiful cash. CRBU is up just 9% since then, despite positive updates and…
fcafotodigital/E+ via Getty Images Coherus BioSciences, Inc. (NASDAQ:CHRS) is a commercial-stage biopharmaceutical company, that markets a few biosimilars and on October 27, 2023, achieved FDA approval of a new drug, Loqtorzi (toripalimab). Further, CHRS saw the approval of a new form of one of its biosimilars, Udenyca Onbody, in December 2023. This article takes a…
Pgiam/iStock via Getty Images Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is staying depressed because of the failure of a Phase 3 study for pitolisant in patients with Idiopathic Hypersomnia, challenges from short sellers, increasing doubts about its patent estate, doubt about the value of its Zynerba acquisition, and increasing competition from a few rivals, including Axsome…
wimagine/iStock via Getty Images Topline Summary Arcus Biosciences (NYSE:RCUS) is a developmental biotech pursuing several different anticancer therapies, including iterations of immune checkpoint blockers with targets both established and still hypothetical. A recent presentation of a phase 2 study provides an interesting signal of the efficacy of their PD-1/TIGIT combination in patients with esophagogastric cancer,…
designer491 Shares of Neurocrine Biosciences (NASDAQ:NBIX) have been stuck in a range recently due to a combination of a lack of appreciation for good news on the clinical side with two phase 3 trial wins for crinecerfont and the continued strong growth of Ingrezza, and some market “appreciation” on the downside due to the two…
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Priyam Shah – Head of Investor Relations Brian McKelligon – Chief Executive Officer Johnny Ek – Chief Financial Officer Conference Call Participants Edmund Tu – Morgan Stanley Kyle Mikson – Canaccord Genuity Timothy Chiang – Capital One Mason…
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants T.J. Schaefer – Chief Financial Officer Stan Jacot – President and Chief Executive Officer Conference Call Participants Dipesh Patel – H.C. Wainwright & Co Ben Klieve – Lake Street Capital Markets Operator Good afternoon and welcome to Arcadia…
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Pia Eaves – Head of Investor Relations And Strategy Terry Rosen – Co-Founder, Chairman & CEO Dimitry Nuyten – Chief Medical Officer Jennifer Jarrett – COO & Director Robert Goeltz – Principal Financial & Accounting Officer & CFO…
Ralf Hahn It has been over a year since I have taken a closer look at Pacira BioSciences (NASDAQ:PCRX) and the company’s performance, and a brief review points to a company that is dealing with multiple challenges that have impacted their growth trajectory. As a result, the market has punished PCRX and the ticker has…
MF3d Sometimes knowing what you don’t know is as critical as what you do. Biotech is a good example. I can talk electronics all day long, but biotech is another black magic, where I need to google half the buzzwords and everything looks shiny and bright. I remember the first golden age of biotech in…
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Paul Goodson – IR Wenbin Jiang – CEO Patrik Jeanmonod – CFO Conference Call Participants Steven Mah – TD Cowen David Westenberg – Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Cytek…
Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications and Investor Relations William Rice – Chairman, President and Chief Executive Officer Rafael Bejar – Senior Vice President and Chief Medical Officer Fletcher Payne – Senior Vice President and Chief Financial Officer Conference…
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Todd Tushla – VP, IR Kevin Gorman – CEO Matt Abernethy – CFO Eiry Roberts – Chief Medical Officer Eric Benevich – Chief Commercial Officer Kyle Gano – Chief Business Development & Strategy Officer Conference Call Participants Paul…